Concurrent Chemotherapy and Re-irradiation for Locoregionally Recurrent Head and Neck Cancer

Seminars in Oncology

Volumn 35, Issue 3, 2008, Pages 251-261

  Salama, Joseph K ^a   Vokes, Everett E ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; AMIFOSTINE; BEVACIZUMAB; BORTEZOMIB; CARBOPLATIN; CISPLATIN; DOCETAXEL; FLUOROURACIL; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; HYDROXYUREA; IRINOTECAN; PACLITAXEL; PEMETREXED; REPLICATION DEFICIENT ADENOVIRAL SEROTYPE 5 VECTOR; TIRAPAZAMINE; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN ANTIBODY;

ANEMIA; ARTICLE; BLEEDING; BLOOD TOXICITY; BONE NECROSIS; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CAROTID ARTERY BLEEDING; CAROTID BLEEDING; CERVICAL FIBROSIS; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTINUOUS INFUSION; CYTOREDUCTIVE SURGERY; DEHYDRATION; DERMATITIS; DIARRHEA; DRUG FATALITY; DRUG POTENTIATION; DYSPHAGIA; FIBROSIS; FISTULA; GASTROINTESTINAL TOXICITY; HAND FOOT SYNDROME; HEAD AND NECK CANCER; HEARING LOSS; HUMAN; INFECTION; LARYNX DISORDER; LEUKOPENIA; MONOTHERAPY; MUCOSA INFLAMMATION; MUCOSAL NECROSIS; MULTIPLE CYCLE TREATMENT; NECROSIS; NEUTROPENIA; OTITIS; PAIN; PHARYNX DISEASE; PNEUMONIA; PRIORITY JOURNAL; RADIATION DOSE; RADIOSENSITIVITY; RECURRENT CANCER; SOFT TISSUE DISEASE; TEMPORAL LOBE NECROSIS; THROMBOSIS; TISSUE NECROSIS; TREATMENT OUTCOME; TRISMUS; VASCULAR DISEASE;

CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; HEAD AND NECK NEOPLASMS; HUMANS; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, SECOND PRIMARY; RADIOTHERAPY; SALVAGE THERAPY;

EID: 44649192277     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2008.03.010     Document Type: Article

References (76)

1. Bernier J., Domenge C., Ozsahin M., Matuszewska K., Lefebvre J.L., Greiner R.H., et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med 350 (2004) 1945-1952
2. Cooper J.S., Pajak T.F., Forastiere A.A., Jacobs J., Campbell B.H., Saxman S.B., et al. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med 350 (2004) 1937-1944
3. Forastiere A.A., Goepfert H., Maor M., Pajak T.F., Weber R., Morrison W., et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 349 (2003) 2091-2098
4. Brockstein B., Haraf D.J., Rademaker A.W., Kies M.S., Stenson K.M., Rosen F., et al. Patterns of failure, prognostic factors and survival in locoregionally advanced head and neck cancer treated with concomitant chemoradiotherapy: a 9-year, 337-patient, multi-institutional experience. Ann Oncol 15 (2004) 1179-1186
5. Khuri F.R., Lee J.J., Lippman S.M., Kim E.S., Cooper J.S., Benner S.E., et al. Randomized phase III trial of low-dose isotretinoin for prevention of second primary tumors in stage I and II head and neck cancer patients. J Natl Cancer Inst 98 (2006) 441-450
6. Lin K., Patel S.G., Chu P.Y., Matsuo J.M., Singh B., Wong R.J., et al. Second primary malignancy of the aerodigestive tract in patients treated for cancer of the oral cavity and larynx. Head Neck 27 (2005) 1042-1048
7. Schwartz L.H., Ozsahin M., Zhang G.N., Touboul E., De Vataire F., Andolenko P., et al. Synchronous and metachronous head and neck carcinomas. Cancer 74 (1994) 1933-1938
8. Spector J.G., Sessions D.G., Haughey B.H., Chao K.S., Simpson J., El Mofty S., et al. Delayed regional metastases, distant metastases, and second primary malignancies in squamous cell carcinomas of the larynx and hypopharynx. Laryngoscope 111 (2001) 1079-1087
9. Vikram B., Strong E.W., Shah J.P., and Spiro R. Second malignant neoplasms in patients successfully treated with multimodality treatment for advanced head and neck cancer. Head Neck Surg 6 (1984) 734-737
10. Cooper J.S., Pajak T.F., Rubin P., Tupchong L., Brady L.W., Leibel S.A., et al. Second malignancies in patients who have head and neck cancer: incidence, effect on survival and implications based on the RTOG experience. Int J Radiat Oncol Biol Phys 17 (1989) 449-456
11. Bairati I., Meyer F., Gelinas M., Fortin A., Nabid A., Brochet F., et al. A randomized trial of antioxidant vitamins to prevent second primary cancers in head and neck cancer patients. J Natl Cancer Inst 97 (2005) 481-488
12. Ganly I., Patel S.G., Matsuo J., Singh B., Kraus D.H., Boyle J.O., et al. Results of surgical salvage after failure of definitive radiation therapy for early-stage squamous cell carcinoma of the glottic larynx. Arch Otolaryngol Head Neck Surg 132 (2006) 59-66
13. McLaughlin M.P., Parsons J.T., Fein D.A., Stringer S.P., Cassisi N.J., Mendenhall W.M., et al. Salvage surgery after radiotherapy failure in T1-T2 squamous cell carcinoma of the glottic larynx. Head Neck 18 (1996) 229-235
14. Wong L.Y., Wei W.I., Lam L.K., and Yuen A.P. Salvage of recurrent head and neck squamous cell carcinoma after primary curative surgery. Head Neck 25 (2003) 953-959
15. Parsons J.T., Mendenhall W.M., Stringer S.P., Cassisi N.J., and Million R.R. Salvage surgery following radiation failure in squamous cell carcinoma of the supraglottic larynx. Int J Radiat Oncol Biol Phys 32 (1995) 605-609
16. Marcial V.A., Hanley J.A., Ydrach A., and Vallecillo L.A. Tolerance of surgery after radical radiotherapy of carcinoma of the oropharynx. Cancer 46 (1980) 1910-1912
17. Temam S., Pape E., Janot F., Wibault P., Julieron M., Lusinchi A., et al. Salvage surgery after failure of very accelerated radiotherapy in advanced head-and-neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys 62 (2005) 1078-1083
18. Mabanta S.R., Mendenhall W.M., Stringer S.P., and Cassisi N.J. Salvage treatment for neck recurrence after irradiation alone for head and neck squamous cell carcinoma with clinically positive neck nodes. Head Neck 21 (1999) 591-594
19. Clavel M., Vermorken J.B., Cognetti F., Cappelaere P., de Mulder P.H., Schornagel J.H., et al. Randomized comparison of cisplatin, methotrexate, bleomycin and vincristine (CABO) versus cisplatin and 5-fluorouracil (CF) versus cisplatin (C) in recurrent or metastatic squamous cell carcinoma of the head and neck. A phase III study of the EORTC Head and Neck Cancer Cooperative Group. Ann Oncol 5 (1994) 521-526
20. Argiris A., Li Y., and Forastiere A. Prognostic factors and long-term survivorship in patients with recurrent or metastatic carcinoma of the head and neck. Cancer 101 (2004) 2222-2229
21. Hitt R., Irigoyen A., Nuñez J., Grau J., Garcia Saenz J., Pastor M., et al. Phase II study of combination cetuximab and weekly paclitaxel in patients with metastatic/recurrent squamous cell carcinoma of head and neck (SCCHN): Spanish Head and Neck Cancer Group (TTCC). [abstract]. J Clin Oncol 25 Suppl 18 (2007) 6012
22. Kim E.S., Kies M.S., Glisson B.S., Tsao A., Ginsberg L.E., Holsinger F.C., et al. Final results of a phase II study of erlotinib, docetaxel and cisplatin in patients with recurrent/metastatic head and neck cancer. [abstact]. J Clin Oncol 25 Suppl 18 (2007) 6013
23. Emami B., Bignardi M., Spector G.J., Devineni V.R., and Hederman M.A. Reirradiation of recurrent head and neck cancers. Laryngoscope 97 (1987) 85-88
24. Stevens Jr. K.R., Britsch A., and Moss W.T. High-dose reirradiation of head and neck cancer with curative intent. Int J Radiat Oncol Biol Phys 29 (1994) 687-698
25. Peiffert D., Pernot M., Malissard L., Aletti P., Hoffstetter S., Kozminski P., et al. Salvage irradiation by brachytherapy of velotonsillar squamous cell carcinoma in a previously irradiated field: results in 73 cases. Int J Radiat Oncol Biol Phys 29 (1994) 681-686
26. Weichselbaum R.R., Beckett M.A., Schwartz J.L., and Dritschilo A. Radioresistant tumor cells are present in head and neck carcinomas that recur after radiotherapy. Int J Radiat Oncol Biol Phys 15 (1988) 575-579
27. Seiwert T.Y., Salama J.K., and Vokes E.E. The concurrent chemoradiation paradigm-general principles. Nat Clin Pract Oncol 4 (2007) 86-100
28. Withers H.R., Taylor J.M., and Maciejewski B. The hazard of accelerated tumor clonogen repopulation during radiotherapy. Acta Oncol 27 (1988) 131-146
29. Schmidt-Ullrich R.K., Contessa J.N., Dent P., Mikkelsen R.B., Valerie K., Reardon D.B., et al. Molecular mechanisms of radiation-induced accelerated repopulation. Radiat Oncol Investig 7 (1999) 321-330
30. Uchida D., Kawamata H., Omotehara F., Nakashiro K., Kimura-Yanagawa T., Hino S., et al. Role of HGF/c-met system in invasion and metastasis of oral squamous cell carcinoma cells in vitro and its clinical significance. Int J Cancer 93 (2001) 489-496
31. Khodarev N.N., Beckett M., Labay E., Darga T., Roizman B., and Weichselbaum R.R. STAT1 is overexpressed in tumors selected for radioresistance and confers protection from radiation in transduced sensitive cells. Proc Natl Acad Sci U S A 101 (2004) 1714-1719
32. Dey S., Spring P.M., Arnold S., Valentino J., Chendil D., Regine W.F., et al. Low-dose fractionated radiation potentiates the effects of Paclitaxel in wild-type and mutant p53 head and neck tumor cell lines. Clin Cancer Res 9 (2003) 1557-1565
33. Connell P.P., Jayathilaka K., Haraf D.J., Weichselbaum R.R., Vokes E.E., and Lingen M.W. Pilot study examining tumor expression of RAD51 and clinical outcomes in human head cancers. Int J Oncol 28 (2006) 1113-1119
34. Mauceri H.J., Hanna N.N., Beckett M.A., Gorski D.H., Staba M.J., Stellato K.A., et al. Combined effects of angiostatin and ionizing radiation in antitumour therapy. Nature 394 (1998) 287-291
35. DeLaney T.F., Afridi N., Taghian A.G., Sanders D.A., Fuleihan N.S., Faller D.V., et al. 13-Cis-retinoic acid with alpha-2a-interferon enhances radiation cytotoxicity in head and neck squamous cell carcinoma in vitro. Cancer Res 56 (1996) 2277-2280
36. Vokes E.E., Beckett M., Karrison T., and Weichselbaum R.R. The interaction of 5-fluorouracil, hydroxyurea, and radiation in two human head and neck cancer cell lines. Oncology 49 (1992) 454-460
37. Hong W.K., and Bromer R. Chemotherapy in head and neck cancer. N Engl J Med 308 (1983) 75-79
38. Spencer S.A., Harris J., Wheeler R.H., Machtay M., Schultz C., Spanos W., et al. RTOG 96-10: reirradiation with concurrent hydroxyurea and 5-fluorouracil in patients with squamous cell cancer of the head and neck. Int J Radiat Oncol Biol Phys 51 (2001) 1299-1304
39. De Crevoisier R., Bourhis J., Domenge C., Wibault P., Koscielny S., Lusinchi A., et al. Full-dose reirradiation for unresectable head and neck carcinoma: experience at the Gustave-Roussy Institute in a series of 169 patients. J Clin Oncol 16 (1998) 3556-3562
40. Haraf D.J., Weichselbaum R.R., and Vokes E.E. Re-irradiation with concomitant chemotherapy of unresectable recurrent head and neck cancer: a potentially curable disease. Ann Oncol 7 (1996) 913-918
41. Salama J.K., Vokes E.E., Chmura S.J., Milano M.T., Kao J., Stenson K.M., et al. Long-term outcome of concurrent chemotherapy and reirradiation for recurrent and second primary head-and-neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys 64 (2006) 382-391
42. Milano M.T., Vokes E.E., Salama J.K., Stenson K.M., Kao J., Witt M.E., et al. Twice-daily reirradiation for recurrent and second primary head-and-neck cancer with gemcitabine, paclitaxel, and 5-fluorouracil chemotherapy. Int J Radiat Oncol Biol Phys 61 (2005) 1096-1106
43. Chmura S.J., Vokes E.E., Garofalo M., Stenson K., Witt M., Weichselbaum R.R., et al. Long-term outcome of re-irradiation with concomitant chemotherapy for locally recurrent squamous cell carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 57 Suppl (2003) S409-S410
44. Brockstein B., Haraf D.J., Stenson K., Fasanmade A., Stupp R., Glisson B., et al. Phase I study of concomitant chemoradiotherapy with paclitaxel, fluorouracil, and hydroxyurea with granulocyte colony-stimulating factor support for patients with poor-prognosis cancer of the head and neck. J Clin Oncol 16 (1998) 735-744
45. Kramer N.M., Horwitz E.M., Cheng J., Ridge J.A., Feigenberg S.J., Cohen R.B., et al. Toxicity and outcome analysis of patients with recurrent head and neck cancer treated with hyperfractionated split-course reirradiation and concurrent cisplatin and paclitaxel chemotherapy from two prospective phase I and II studies. Head Neck 27 (2005) 406-414
46. Langer C.J., Duffy K., Horwitz E.M., Litwin S., Rosvold E., Schol J., et al. Phase I trial of concurrent hyperfractionated split course radiotherapy (HFx RT), cisplatin (cDDP), and paclitaxel in patients with recurrent, previously irradiated, or treatment-naive locally advanced upper aerodigestive malignancy. Cancer Invest 24 (2006) 164-173
47. Horwitz E.M., Harris J., Langer C.J., Nicolaou N., Kies M., Curran W., et al. Concurrent split course hyperfractionated radiotherapy (Hfx RT), cisplatin (DDP) and paclitaxel (P) in patients with recurrent, previously irradiated squamous cell carcinoma of the head and neck (SCCHN): update of RTOG 9911. [abstract]. J Clin Oncol 23 Suppl 16 (2005) 5577
48. Janot F., de Raucourt D., Castaing M., Bardet E., and Dolivet G. Re-irradiation combined with chemotherapy after salvage surgery in head and neck carcinoma: a randomized trial from the GETTEC and GORTEC groups. [abstract]. J Clin Oncol 24 Suppl 18 (2006) 5508
49. Spencer S., Wheeler R., Peters G., Meredith R., Beenken S., Nabel L., et al. Phase 1 trial of combined chemotherapy and reirradiation for recurrent unresectable head and neck cancer. Head Neck 25 (2003) 118-122
50. Calais G., Alfonsi M., Bardet E., Sire C., Germain T., Bergerot P., et al. Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced-stage oropharynx carcinoma. J Natl Cancer Inst 91 (1999) 2081-2086
51. Spencer S.H.J., Wheeler R., Mactay M., Schultz C., Spanos W., Rotman M., et al. Late effects of RTOG-9610: re-irradiation and chemotherapy in patients with squamous cell cancer of the head and neck. Int J Radiat Oncol Biol Phys 57 (2003) S307
52. Machtay M., Rosenthal D.I., Chalian A.A., Lustig R., Hershock D., Miller L., et al. Pilot study of postoperative reirradiation, chemotherapy, and amifostine after surgical salvage for recurrent head-and-neck cancer. Int J Radiat Oncol Biol Phys 59 (2004) 72-77
53. Ang K.K., Jiang G.L., Feng Y., Stephens L.C., Tucker S.L., and Price R.E. Extent and kinetics of recovery of occult spinal cord injury. Int J Radiat Oncol Biol Phys 50 (2001) 1013-1020
54. De Crevoisier R., Domenge C., Wibault P., Koscielny S., Lusinchi A., Janot F., et al. Full dose reirradiation combined with chemotherapy after salvage surgery in head and neck carcinoma. Cancer 91 (2001) 2071-2076
55. Kasperts N., Slotman B.J., Leemans C.R., de Bree R., Doornaert P., and Langendijk J.A. Results of postoperative reirradiation for recurrent or second primary head and neck carcinoma. Cancer 106 (2006) 1536-1547
56. Upile T., Triaridis S., Kirkland P., Archer D., Searle A., Irving C., et al. The management of carotid artery rupture. Eur Arch Otorhinolaryngol 262 (2005) 555-560
57. Skelly C.L., Gallagher K., Fairman R.M., Carpenter J.P., Velazquez O.C., Parmer S.S., et al. Risk factors for restenosis after carotid artery angioplasty and stenting. J Vasc Surg 44 (2006) 1010-1015
58. Haddad R., Tishler R., Wirth L., Norris C.M., Goguen L., Sullivan C., et al. Rate of pathologic complete responses to docetaxel, cisplatin, and fluorouracil induction chemotherapy in patients with squamous cell carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg 132 (2006) 678-681
59. Urba S., Wolf G., Eisbruch A., Worden F., Lee J., Bradford C., et al. Single-cycle induction chemotherapy selects patients with advanced laryngeal cancer for combined chemoradiation: a new treatment paradigm. J Clin Oncol 24 (2006) 593-598
60. Cohen E.E., Rosine D., Haraf D.J., Loh E., Shen L., Lusinchi A., et al. Phase I trial of tirapazamine, cisplatin, and concurrent accelerated boost reirradiation in patients with recurrent head and neck cancer. Int J Radiat Oncol Biol Phys 67 (2007) 678-684
61. 18F]-misonidazole positron emission tomography-detected tumor hypoxia in patients with advanced head and neck cancer randomly assigned to chemoradiation with or without tirapazamine: a substudy of Trans-Tasman Radiation Oncology Group Study 98.02. J Clin Oncol 24 (2006) 2098-2104
62. Gorski D.H., Beckett M.A., Jaskowiak N.T., Calvin D.P., Mauceri H.J., Salloum R.M., et al. Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation. Cancer Res 59 (1999) 3374-3378
63. Wachsberger P., Burd R., and Dicker A.P. Tumor response to ionizing radiation combined with antiangiogenesis or vascular targeting agents: exploring mechanisms of interaction. Clin Cancer Res 9 (2003) 1957-1971
64. Seiwert T.Y., Haraf D.J., Cohen E.E., Stenson K., Mauer A.M., Dekker A., et al. A phase I study of bevacizumab (B) with fluorouracil (F) and hydroxyurea (H) with concomitant radiotherapy (X) (B-FHX) for poor prognosis head and neck cancer (HNC). [abstract]. J Clin Oncol 24 Suppl 18 (2006) 5530
65. Hallahan D.E., Mauceri H.J., Seung L.P., Dunphy E.J., Wayne J.D., Hanna N.N., et al. Spatial and temporal control of gene therapy using ionizing radiation. Nat Med 1 (1995) 786-791
66. Mundt A.J., Vijayakumar S., Nemunaitis J., Sandler A., Schwartz H., Hanna N., et al. A phase I trial of TNFerade biologic in patients with soft tissue sarcoma in the extremities. Clin Cancer Res 10 (2004) 5747-5753
67. Sulman E.P., Schwartz D.L., Morrison W.H., Rosenthal D.I., Chao K.S., Ahamada A., et al. IMRT re-irradiation for locoregionally recurrent or in-field second primary head and neck cancer. Int J Radiat Oncol Biol Phys 66 (2006) S412-S413
68. Jereczek-Fossa B.A., Krengli M., and Orecchia R. Particle beam radiotherapy for head and neck tumors: radiobiological basis and clinical experience. Head Neck 28 (2006) 750-760
69. Luu Q.T., Loredo L.N., Archambeau J.O., Yonemoto L.T., Slater J.M., and Slater J.D. Fractionated proton radiation treatment for pediatric craniopharyngioma: preliminary report. Cancer J 12 (2006) 155-159
70. Wilson V.C., McDonough J., and Tochner Z. Proton beam irradiation in pediatric oncology: an overview. J Pediatr Hematol Oncol 27 8 (2005) 444-448
71. Dendale R., Lumbroso-Le Rouic L., Noel G., Feuvret L., Levy C., Delacroix S., Meyer A., Nauraye C., Mazal A., and Mammar H. Proton beam radiotherapy for uveal melanoma: results of Curie Institut-Orsay proton therapy center (ICPO). others. Int J Radiat Oncol Biol Phys 65 3 (2006) 780-787
72. Fuss M., Loredo L.N., Blacharski P.A., Grove R.I., and Slater J.D. Proton radiation therapy for medium and large choroidal melanoma: preservation of the eye and its functionality. Int J Radiat Oncol Biol Phys 49 4 (2001) 1053-1059
73. Gragoudas E.S., Lane A.M., Munzenrider J., Egan K.M., and Li W. Long-term risk of local failure after proton therapy for choroidal/ciliary body melanoma. Trans Am Ophthalmol Soc 100 (2002) 43-48 discussion 48-9
74. Hara I., Murakami M., Kagawa K., Sugimura K., Kamidono S., Hishikawa Y., and Abe M. Experience with conformal proton therapy for early prostate cancer. Am J Clin Oncol 27 4 (2004) 323-327
75. Trabulsi E.J., and Valicenti R.K. Dose escalation with proton-beam boost for low-risk prostate cancer. Nat Clin Pract Urol 3 5 (2006) 256-257
76. Van Waes C., Chang A.A., Lebowitz P.F., Druzgal C.H., Chen Z., Elsayed Y.A., et al. Inhibition of nuclear factor kappaB and target genes during combined therapy with proteosome inhibitor bortezomib and reirradiation in patients with recurrent head-and-neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys 63 (2005) 1400-1412